[18F]florbetaben has been granted a Fast Track designation for cardiac amyloidosis, which will expedite the development of [18F]florbetaben for this indication [18F]florbetaben previously received ...

[18F]florbetaben has been granted a Fast Track designation for cardiac amyloidosis, which will expedite the development of [18F]florbetaben for this indication [18F]florbetaben previously received ...

at 3T is becoming more common and may pose a different risk profile and outcome of MRI of cardiac device patients. Methods: No restrictions were placed on pacemaker dependency, region scanned ...

124 I-evuzamitide has received Breakthrough Therapy Designation from the Food and Drug Administration (FDA) for PET imaging in patients with suspected or known cardiac amyloidosis. 124 I ...

The trial is designed to determine the sensitivity and specificity of 124 I-evuzamitide imaging to diagnose cardiac amyloidosis. “This study seeks to add significant value for patient care ...

a clinical stage biopharmaceutical company developing transformative products to improve the lives of patients with systemic amyloidosis, and Brigham and Women's Hospital, Boston, MA, are pleased to ...

a clinical stage biopharmaceutical company developing transformative products to improve the lives of patients with systemic amyloidosis, and Brigham and Women’s Hospital, Boston, MA, are pleased to ...

During a cardiac arrest, when oxygen supply is cut off, these cells die. Instead of growing back, they’re replaced by scar tissue, which doesn’t work like healthy heart muscle. This can weaken ...

Introduction: Sleep deprivation (SD) significantly disrupts the homeostasis of the cardiac-brain axis, yet the neuromodulation effects of deep ... All individuals underwent heart sound measurements ...

This is a condition in which your heart is unable to pump blood through your body effectively. Amyloid deposits also interfere with your heart’s electrical system and can cause cardiac arrhythmia (an ...